Viela Bio (VIE) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Viela Bio (VIE) Misses Q1 EPS by 8c

Viela Bio (VIE) Reports Positive Interim Results from Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus

May 13, 2020 4:22 PM EDT

Viela Bio, Inc. (NASDAQ: VIE) today announced positive interim Phase 1b data from a study with VIB7734, its novel anti-ILT7 therapy, in patients with cutaneous lupus erythematosus (CLE). VIB7734 was designed to deplete plasmacytoid dendritic cells (pDCs), an important source of inflammatory mediators in autoimmune diseases. This trial includes three cohorts of patients at ascending dose levels. Cohorts 2 and 3 enrolled patients with CLE. Key measures include safety and tolerability, pDC depletion in peripheral blood and skin lesions of patients with CLE, and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores. Interim... More